Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer. It is marketed in the US by AstraZeneca under brand Lynparza.